Impact and cost-effectiveness of current and future tuberculosis diagnostics: the contribution of modelling

被引：14

作者：

Dowdy, D. W. ^{[1
]}

Houben, R. ^{[2
]}

Cohen, T. ^{[3
]}

Pai, M. ^{[4
,5
]}

Cobelens, F. ^{[6
,7
]}

Vassall, A. ^{[8
]}

Menzies, N. A. ^{[9
]}

Gomez, G. B. ^{[6
,7
]}

Langley, I. ^{[10
,11
]}

Squire, S. B. ^{[10
,11
]}

White, R. ^{[2
]}

机构：

[1] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA

[2] Univ London London Sch Hyg & Trop Med, Epidemiol & TB Modelling Grp, Dept Infect Dis, London WC1E 7HT, England

[3] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA

[4] McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada

[5] McGill Univ, McGill Int TB Ctr, Montreal, PQ, Canada

[6] Univ Amsterdam, Acad Med Ctr, Dept Global Hlth, NL-1105 AZ Amsterdam, Netherlands

[7] Univ Amsterdam, Acad Med Ctr, Amsterdam Inst Global Hlth & Dev, NL-1105 AZ Amsterdam, Netherlands

[8] Univ London London Sch Hyg & Trop Med, Dept Global Hlth & Dev, SAME Modelling & Econ, London WC1E 7HT, England

[9] Harvard Univ, Sch Publ Hlth, Ctr Hlth Decis Sci, Boston, MA 02115 USA

[10] Univ Liverpool, Liverpool Sch Trop Med, Dept Clin Sci, Liverpool L3 5QA, Merseyside, England

[11] Univ Liverpool, Liverpool Sch Trop Med, Ctr Appl Hlth Res & Delivery, Liverpool L3 5QA, Merseyside, England

来源：

INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE | 2014年 / 18卷 / 09期

关键词：

tuberculosis; modelling; diagnostics; POINT-OF-CARE; XPERT MTB/RIF; AFRICA; BURDEN; TESTS; PYRAZINAMIDE; FRAMEWORK; DISEASE; DRUGS;

D O I：

10.5588/ijtld.13.0851

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The landscape of diagnostic testing for tuberculosis (TB) is changing rapidly, and stakeholders need urgent guidance on how to develop, deploy and optimize TB diagnostics in a way that maximizes impact and makes best use of available resources. When decisions must be made with only incomplete or preliminary data available, modelling is a useful tool for providing such guidance. Following a meeting of modelers and other key stakeholders organized by the TB Modelling and Analysis Consortium, we propose a conceptual framework for positioning models of TB diagnostics. We use that framework to describe modelling priorities in four key areas: Xpert (R) MTB/RIF scale-up, target product profiles for novel assays, drug susceptibility testing to support new drug regimens, and the improvement of future TB diagnostic models. If we are to maximize the impact and cost-effectiveness of TB diagnostics, these modelling priorities should figure prominently as targets for future research.

引用

页码：1012 / 1018

页数：7

共 50 条

[31] Cost-effectiveness of Xpert® MTB/RIF for diagnosing pulmonary tuberculosis in the United States [J].

Choi, H. W. ;

Miele, K. ;

Dowdy, D. ;

Shah, M. .

INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2013, 17 (10) :1328-1335

[32] Cost-effectiveness of a Pharmacogenomic Test for Stratified Isoniazid Dosing in Treatment of Active Tuberculosis [J].

Rens, Neil E. ;

Uyl-de Groot, Carin A. ;

Goldhaber-Fiebert, Jeremy D. ;

Croda, Julio ;

Andrews, Jason R. .

CLINICAL INFECTIOUS DISEASES, 2020, 71 (12) :3136-3143

[33] Cost-effectiveness of a new strategy to detect pulmonary tuberculosis in household contacts in Myanmar [J].

Htet, K. K. K. ;

Liabsuetrakul, T. ;

Thein, S. .

INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2017, 21 (02) :181-187

[34] Impact of assumptions on future costs, disutility and mortality in cost-effectiveness analysis; a model exploration [J].

Omidvari, Amir-Houshang ;

Lansdorp-Vogelaar, Iris ;

de Koning, Harry J. ;

Meester, Reinier G. S. ;

Geisler, Benjamin P. .

PLOS ONE, 2021, 16 (07)

[35] The potential impact and cost-effectiveness of tobacco reduction strategies for tuberculosis prevention in Canadian Inuit communities [J].

Dieynaba S. N’Diaye ;

Ntwali Placide Nsengiyumva ;

Aashna Uppal ;

Olivia Oxlade ;

Gonzalo G. Alvarez ;

Kevin Schwartzman .

BMC Medicine, 17

[36] Feasibility of novel adult tuberculosis vaccination in South Africa: a cost-effectiveness and budget impact analysis [J].

Jayawardana, Sahan ;

Weerasuriya, Chathika K. ;

Pelzer, Puck T. ;

Seeley, Janet ;

Harris, Rebecca C. ;

Tameris, Michele ;

Tait, Dereck ;

White, Richard G. ;

Asaria, Miqdad .

NPJ VACCINES, 2022, 7 (01)

[37] The potential impact and cost-effectiveness of tobacco reduction strategies for tuberculosis prevention in Canadian Inuit communities [J].

N'Diaye, Dieynaba S. ;

Nsengiyumva, Ntwali Placide ;

Uppal, Aashna ;

Oxlade, Olivia ;

Alvarez, Gonzalo G. ;

Schwartzman, Kevin .

BMC MEDICINE, 2019, 17 (1)

[38] Potential cost-effectiveness of rifampin vs. isoniazid for latent tuberculosis: implications for future clinical trials [J].

Esfahani, K. ;

Aspler, A. ;

Menzies, D. ;

Schwartzman, K. .

INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2011, 15 (10) :1340-1346

[39] Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia [J].

Floyd, Katherine ;

Hutubessy, Raymond ;

Kliiman, Kai ;

Centis, Rosella ;

Khurieva, Nina ;

Jakobowiak, Wieslaw ;

Danilovits, Manfred ;

Peremitin, Genadi ;

Keshavjee, Salmaan ;

Migliori, Giovanni Battista .

EUROPEAN RESPIRATORY JOURNAL, 2012, 40 (01) :133-142

[40] Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis [J].

G. B. Gomez ;

D. W. Dowdy ;

M. L. Bastos ;

A. Zwerling ;

S. Sweeney ;

N. Foster ;

A. Trajman ;

M. A. Islam ;

S. Kapiga ;

E. Sinanovic ;

G. M. Knight ;

R. G. White ;

W. A. Wells ;

F. G. Cobelens ;

A. Vassall .

BMC Infectious Diseases, 16

← 1 2 3 4 5 →